文献速递肝病

2型糖尿病患者中无创评分诊断纤维化型代谢功能障碍相关脂肪性肝炎的前瞻性头对头比较

Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
PubMed 文献 · J Hepatol · 2024-03-27

多中心前瞻性研究纳入330例经活检证实的MASLD的2型糖尿病门诊患者,对FAST、MAST、MEFIB和FNI四种无创评分进行头对头比较。245例数据完整者中纤维化型MASH占39%。FAST与MAST准确性相似(AUROC 0.81 vs 0.79,p=0.41),均优于FNI(0.74;p=0.01)和MEFIB(0.68;p<0.0001)。

要点

  • FAST与MAST诊断纤维化型MASH准确性相似,均优于FNI和MEFIB。
  • 使用原始截断值时,MAST正确分类比例最高(69%)。
  • 使用本研究人群特异性截断值时,FAST正确分类比例最高(56%)。

核心结论

  • FAST、MAST、MEFIB和FNI均是识别二级/三级糖尿病门诊中2型糖尿病合并纤维化型MASH患者的准确无创工具。
  • 作者认为应考虑采用适配2型糖尿病患者的截断值。

研究设计与样本

  • 多中心前瞻性研究,来自QUID-NASH研究(NCT03634098),共330例经活检证实的MASLD的2型糖尿病门诊患者。
  • 患者在接受肝活检时完成FibroScan、MRI质子密度脂肪分数和磁共振弹性成像检查。
  • 主要结局为纤维化型MASH,定义为NAS≥4(每项参数至少1分)且纤维化分期≥2(中心化复核)。
  • 评分比较数据完整的患者共245例:中位年龄59岁,男性65%,中位BMI 31 kg/m2,纤维化型MASH占39%。

主要发现

  • FAST与MAST准确性相似(AUROC 0.81 vs 0.79,p=0.41),但均优于FNI(0.74;p=0.01)和MEFIB(0.68;p<0.0001)。
  • 使用原始截断值时,可避免肝活检的正确分类患者比例MAST为69%,FAST为48%,MEFIB为46%,FNI为39%(p<0.001)。
  • 使用本研究人群特异性截断值时,正确分类患者比例FAST为56%,FNI为40%,MAST为38%(p<0.001)。

临床怎么用

  • 作者认为FAST、MAST、MEFIB和FNI可用于识别二级/三级糖尿病门诊中2型糖尿病合并纤维化型MASH的患者。
  • 作者认为应考虑采用适配2型糖尿病患者的截断值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-invasive scores have been proposed to identify patients with fibrotic, metabolic dysfunction-associated steatohepatitis (MASH), who are at the highest risk of progression to complications of cirrhosis and may benefit from pharmacologic treatments. However, data in patients with type 2 diabetes (T2DM) are lacking. The aim of this multicenter prospective study was to perform a head-to-head comparison of FAST (FibroScan-aspartate aminotransferase [AST]), MAST (MRI-AST), MEFIB (magnetic resonance elastography [MRE] plus FIB-4), and FNI (fibrotic NASH index) for detecting fibrotic MASH in patients with T2DM. METHODS: A total of 330 outpatients with T2DM and biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) from the QUID-NASH study (NCT03634098), who underwent FibroScan, MRI-proton density fat fraction and MRE at the time of liver biopsy were studied. The main outcome was fibrotic MASH, defined as NAS ≥4 (with at least one point for each parameter) and fibrosis stage ≥2 (centrally reviewed). RESULTS: All data for score comparisons were available for 245 patients (median age 59 years, 65% male, median BMI 31 kg/m2; fibrotic MASH in 39%). FAST and MAST had similar accuracy (AUROCs 0.81 vs. 0.79, p = 0.41) but outperformed FNI (0.74; p = 0.01) and MEFIB (0.68; p <0.0001). When using original cut-offs, MAST outperformed FAST, MEFIB and FNI when comparing the percentage of correctly classified patients, in whom liver biopsy would be avoided (69% vs. 48%, 46%, 39%, respectively; p <0.001). When using cut-offs specific to our population, FAST outperformed FNI and MAST (56% vs. 40%, and 38%, respectively; p <0.001). CONCLUSION: Our findings show that FAST, MAST, MEFIB and FNI are accurate non-invasive tools to identify patients with T2DM and fibrotic MASH in secondary/tertiary diabetes clinics. Cut-offs adapted to the T2DM population should be considered. IMPACT AND IMPLICATIONS: Among patients with type 2 diabetes (T2DM), identifying those with metabolic dysfunction-associated steatohepatitis and significant fibrosis, who are the most at risk of developing clinical liver-related outcomes and who may benefit from pharmacologic treatments, is an unmet need. In this prospective multicenter study, we compared four non-invasive scores, three based on imaging (MRI or ultrasound technologies) and one on laboratory blood tests, for this purpose, using original and study-specific cut-offs. Our findings show that FAST, MAST, MEFIB and FNI are accurate non-invasive tools to identify patients with T2DM and fibrotic MASH in secondary/tertiary diabetes clinics. Cut-offs adapted to the T2DM population should be considered. TRIAL REGISTRATION NUMBER: NCT03634098.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Castera L, Garteiser P, Laouenan C, et al. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. J Hepatol. 2024. PMID: 38548067. doi:10.1016/j.jhep.2024.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。